TARGETED THERAPIES Afatinib-new therapy option for EGFR-mutant lung cancer

被引：81

作者：

Yu, Helena A. ^{[1
]}

Pao, William ^{[2
]}

机构：

[1] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Dept Med, Thorac Oncol Serv,Div Solid Tumor Oncol, New York, NY 10065 USA

[2] Vanderbilt Ingram Canc Ctr, Div Hematol Oncol, Nashville, TN 37212 USA

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2013年 / 10卷 / 10期

关键词：

1ST-LINE TREATMENT; OPEN-LABEL; ERLOTINIB; CHEMOTHERAPY; MULTICENTER; PHASE-3; TRIAL;

D O I：

10.1038/nrclinonc.2013.154

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

On 15 July 2013, the FDA approved afatinib as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours harbour exon 19 deletions or exon 21 (L858R) EGFR substitution mutations. We discuss three recent studies investigating afatinib in this molecular subset of patients.

引用

页码：551 / 552

页数：2

共 50 条

[41] A Case of EGFR-mutant Squamous Cell Lung Cancer Treated With Necitumumab Combination Therapy
Inomata, Minehiko
Furukawa, Daisuke
Takata, Naoki
Tokui, Kotaro
Okazawa, Seisuke
Imanishi, Shingo
Nomura, Satoshi
IN VIVO, 2025, 39 (02): : 1207 - 1210
[42] Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
Bian, Dongliang
Sun, Liangdong
Hu, Junjie
Duan, Liang
Xia, Haoran
Zhu, Xinsheng
Sun, Fenghuan
Zhang, Lele
Yu, Huansha
Xiong, Yicheng
Huang, Zhida
Zhao, Deping
Song, Nan
Yang, Jie
Bao, Xiao
Wu, Wei
Huang, Jie
He, Wenxin
Zhu, Yuming
Jiang, Gening
Zhang, Peng
NATURE COMMUNICATIONS, 2023, 14 (01)
[43] Real-world Experience of the Utility in Afatinib Therapy for Patients with EGFR-Mutant Advanced NSCLC
Igawa, S.
Ono, T.
Kasajima, M.
Yamada, K.
Oguri, A.
Kameda, A.
Yamamoto, H.
Kakegawa, M.
Hiyoshi, Y.
Kusuhara, S.
Ozawa, T.
Otani, S.
Fukui, T.
Mitsufuji, H.
Masaru, K.
Yokoba, M.
Kubota, M.
Sasaki, J.
Naoki, K.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S611 - S611
[44] Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations
Liu, Wenliang
Ren, Siying
Xiao, Ying
Yang, Lulu
Zeng, Chao
Hu, Yan
FRONTIERS IN PHARMACOLOGY, 2022, 13
[45] Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study
Lv, Chao
Ma, Yuanyuan
Feng, Qin
Lu, Fangliang
Chi, Yongkun
Wu, Nan
Fang, Jian
Yang, Yue
JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 5324 - +
[46] Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Rabago, Dora Barbosa
Blakely, Collin M.
Haderk, Franziska
Bivona, Trever G.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2021, (177):
[47] Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development
Lampson, Benjamin L.
Nishino, Mizuki
Dahlberg, Suzanne E.
Paul, Danie
Santos, Abigail A.
Jaenne, Pasi A.
Oxnard, Geoffrey R.
CANCER, 2016, 122 (22) : 3456 - 3463
[48] Radiation As a Local Ablative Therapy Option for Oligoprogressive EGFR-Mutant Non-Small Cell Lung Cancer after Treatment with Osimertinib
Kesarwala, A. H.
Kim, C.
Jones, J. C.
Kaushal, A.
Roper, N.
Hoang, C. D.
Szabo, E.
Connolly, M.
Padiernos, E.
Cultraro, C.
Waris, M.
Gao, S.
Steinberg, S. M.
Khan, J.
Rajan, A.
Guha, U.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E467 - E468
[49] Role of tyrosine phosphorylation of β-catenin in EGFR-mutant lung cancer
Fujii, Masanori
Nakayama, Sohei
Shimizu, Kohei
Takei, Hisashi
Ando, Mariko
Heo, Eunyoung
Kobayashi, Ikei
Pan, Gilbert
Inuzuka, Hiroyuki
Kobayashi, Susumu
CANCER RESEARCH, 2018, 78 (13)
[50] Best Initial Treatment Strategies for EGFR-Mutant Lung Cancer
Barber, Emily A.
Reckamp, Karen L.
AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2016, 12 (12) : 4 - 7

← 1 2 3 4 5 →